Moderna Inc (MRNA) Financial Statements

Moderna's financial quality, as assessed by the GoodMoat framework, is weak across key metrics. Revenue growth is sharply negative at -29.8% YoY, indicating a severe contraction rather than the consistent, double-digit growth sought. The company is deeply unprofitable, with a GAAP EPS of -$7.26, an operating margin of -158.1%, and a profit margin of -145.2%, showing no clear near-term path to profitability. Free cash flow generation is also negative, with a FCF Yield of -9.9%, failing the framework's test for positive and growing cash conversion. The sole point of strength is the balance sheet, which shows a very low Debt/Equity ratio of 0.15, indicating minimal financial leverage and substantial liquidity. However, this is overshadowed by contracting margins and a complete lack of operating leverage, as expenses vastly outpace declining revenue. For a value investor focused on durable competitive advantages and financial health, Moderna's current profile does not meet the quality gate, which requires predominantly 'Strong' ratings. The company is in a transitional phase, heavily reliant on its pipeline beyond its COVID-19 products to re-establish growth and profitability. Analysis based on data as of 2024-05-15.